CNBC   |  June 13, 2013

Myriad Hits Historic High

CNBC's Bertha Coombs reports shares of Myriad Genetics are hitting an all-time high after the Supreme Court ruled a naturally occurring human gene cannot be patented, but upheld key DNA patents of Myriad's BRACAnalysis test.

Share This:

Sorry, we do not have a transcript available for this video at this time.